At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Atorvastatin 80 mg orally once dailyAI-extracted
Key inclusion· 9
- ✓Age >18 years
- ✓Confirmed NHL subtype: CLL/SLL, extranodal marginal zone, nodal marginal zone, or splenic marginal zone B-cell lymphoma
- ✓Disease appropriate for watchful waiting (untreated or prior treatment) OR refractory disease
- ✓Staging within 4 weeks (imaging for SLL/marginal zone; labs only for CLL)
Key exclusion· 9
- ✕Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
- ✕Not recovered from adverse events from prior agents (>4 weeks prior)
- ✕Rituximab within 3 months (low-grade) or 1 month (relapsed/refractory)
- ✕Any statin within past 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Atorvastatin in Patients With Low Grade or Refractory Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Atorvastatin for Leukemia and Lymphoma, Non-Hodgkin. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is an approach which can inflict significant toxicity. An alternative is to block expression of oncogenes which are over-expressed only in cancer cells, a therapeutic approach which could reduce toxicity to the host while maximizing destruction of the oncogene-dependent malignant cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma, Non-Hodgkin
CountriesUnited States
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedSep 2005
Primary CompletionNov 2012
TodayJul 2026
First PostedSep 16, 2005
Enrollment StartApr 1, 2005
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 20.8 years ago
Interventions
Atorvastatindrug
80 mg orally once daily